Pfizer: FDA Approves Humira Biosimilar Abrilada for Multiple Conditions
November 18 2019 - 7:29AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug
Administration approved Abrilada, its biosimilar to AbbVie Inc.'s
(ABBV) blockbuster Humira, for multiple inflammatory
conditions.
The New York drug maker said the approval covers the treatment
of certain patients with rheumatoid arthritis, juvenile idiopathic
arthritis, psoriatic arthritis, ankylosing spondylitis, adult
Crohn's disease, ulcerative colitis and plaque psoriasis.
Pfizer said it currently plans to launch Abrilada in the U.S. in
2023 based on the terms of its 2018 licensing agreement with
AbbVie.
Biosimilars are near-copies of biologic drugs, such as Humira,
that are made from living cells and are analogous to generic copies
of traditional pill-form medicines.
Humira, used to treat diseases from rheumatoid arthritis to gut
disorders, is the world's biggest-selling drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 18, 2019 07:14 ET (12:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
